RATIONALE: Mucus hypersecretion with goblet cell hyperplasia is one important feature of allergic rhinitis (AR). However, the mechanisms underlying the remodeling of nasal epithelium in AR are not well understood. b-Galactoside a2,6-sialyltranferase (ST6GAL1) is widely expressed in epithelial cells and participates in the regulation of cell signaling, proliferation, differentiation and apoptosis through processing the sialylated N-glycosylation of proteins. However, the role of ST6GAL1 in AR has been barely studied. METHODS: The protein and mRNA expression levels of ST6GAL1 in nasal tissue biopsies and nasal epithelial cells were detected by immunohistochemistry, western blotting, and real-time PCR analysis. Human nasal epithelial cells (HNECs) scrapped from control subjects were cultured in an air-liquid interface (ALI) condition and transfected with or without ST6GAL1 overexpression plasmid vector. After transfection, cells were treated with or without IL-13. HNECs were then stained with Sambucus nigra lectin (SNA)-FITC and evaluated by flow cytometry. RESULTS: Immunohistochemistry showed that the expression of ST6GAL1 was up-regulated in nasal mucosa from AR patients particularly in nasal epithelial cells. RT-PCR and western blotting analysis confirmed the up-regulation of ST6GAL1 in nasal epithelial cells from AR patients compared with controls. After IL-13 stimulation, the mRNA levels of goblet cell hyperplasia markers, including MUC5AC and FOXA3 besides with ST6GAL1 were elevated in HNECs, and this elevation was more prominent in cells with ST6GAL1 plasmid transfection than those without transfection. IL-13 receptor a2 (IL-13Ra2) of HNECs exhibited increased a2,6-sialylation on N-glycans after overexpression of ST6GAL1. CONCLUSIONS: ST6GAL1 might promote goblet cell hyperplasia induced by IL-13 in AR patients. RATIONALE: Nasal polyps from patients with aspirin-exacerbated respiratory disease (AERD) are defines by a predominant Th2 inflammation environment, and AERD nasal polyps are much more likely to have rapid relapse postoperatively. However, little is known about the specific cellular and molecular mechanisms contributing to the pathogenesis of nasal polyp development in patients with AERD are not present. METHODS: We collected nasal polyp tissue from patients with AERD and from patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Protein profiles were analyzed by 2-dimensional electrophoresis and identified several proteins, including L-plastin, as highly expressed. We examined L-plastin and tissue factor (TF) expression by immunohistochemical and immunofluorescence analyses. To examine the role of L-plastin in eosinophils, we knocked down L-plastin expression in Eol-1 cells by using siRNA transfection. RESULTS: L-plastin protein levels in nasal polyp tissue were increased in patients with AERD relative to those in patients with aspirin tolerant CRSwNP. Immunofluorescence analysis revealed that L-plastin was dominantly expressed in eosinophils and L-plastin and TF were coexpressed in eosinophils in AERD nasal polyp tissue. Silencing of Lplastin in Eol-1 cells disrupted the cell surface distribution of TF by stimulation with granulocyte macrophage colony-stimulating factor. We also found that L-plastin knockdown attenuated transmigration of Eol-1 across the endothelium, and decreased cytokines release.
University of Fukui, Fukui, Japan, 2 Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL. RATIONALE: Nasal polyps from patients with aspirin-exacerbated respiratory disease (AERD) are defines by a predominant Th2 inflammation environment, and AERD nasal polyps are much more likely to have rapid relapse postoperatively. However, little is known about the specific cellular and molecular mechanisms contributing to the pathogenesis of nasal polyp development in patients with AERD are not present. METHODS: We collected nasal polyp tissue from patients with AERD and from patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Protein profiles were analyzed by 2-dimensional electrophoresis and identified several proteins, including L-plastin, as highly expressed. We examined L-plastin and tissue factor (TF) expression by immunohistochemical and immunofluorescence analyses. To examine the role of L-plastin in eosinophils, we knocked down L-plastin expression in Eol-1 cells by using siRNA transfection. RESULTS: L-plastin protein levels in nasal polyp tissue were increased in patients with AERD relative to those in patients with aspirin tolerant CRSwNP. Immunofluorescence analysis revealed that L-plastin was dominantly expressed in eosinophils and L-plastin and TF were coexpressed in eosinophils in AERD nasal polyp tissue. Silencing of Lplastin in Eol-1 cells disrupted the cell surface distribution of TF by stimulation with granulocyte macrophage colony-stimulating factor. We also found that L-plastin knockdown attenuated transmigration of Eol-1 across the endothelium, and decreased cytokines release. CONCLUSIONS: The expression of L-plastin by eosinophils may contribute to abnormal fibrin deposition through TF translocation to the eosinophil cell surface in AERD nasal polyp tissue, which in turn may contribute to the pathogenesis of AERD Attempts to define biomarkers that predict disease activity or relapse in EGPA have proven difficult, and blood absolute eosinophil count (AEC) may not accurately reflect tissue eosinophilia. Although blood and urine levels of eosinophil granule proteins (EGP) correlate with markers of eosinophil activation in other eosinophilic disorders, little is known about their utility in monitoring disease activity in EGPA. METHODS: Urine and plasma were obtained at fixed timepoints from 55 patients with relapsing or refractory EGPA enrolled on a Phase 3 doubleblind, placebo-controlled (NCT02020889) study of mepolizumab (300mg every 4 weeks). Concentrations of major basic protein (MBP), eosinophilic cationic protein (ECP), eosinophil-derived neurotoxin (EDN) and eosinophil peroxidase (EPO) were measured using a suspension array multiplex immunoassay. RESULTS: Plasma EDN (pEDN) and urine EDN (uEDN) levels decreased significantly in the first sample collection following initiation of mepolizumab (pEDN (baseline vs. week 4 (V4)) p<0.0001; uEDN (baseline v. week 24 (V9)) p50.0002), but not placebo. pEDN correlated positively with AEC (R50.57, p<0.0001 [0.33, 0.74] ) and inversely with GC dose. uEDN was not correlated with either parameter. Samples collected within 10 days of a relapse showed higher uEDN concentrations than those collected at the prior visit (GM 1420 vs. 958 ng/mg Cr; p50.01). CONCLUSIONS: In this preliminary analysis, uEDN concentrations declined following mepolizumab treatment, increased with relapses, and were less affected by GC dosing than pEDN, suggesting that uEDN may be a useful biomarker of disease activity in EGPA.
